Cosmo Pharmaceuticals SpA (COPN.S)

COPN.S on Swiss Exchange

177.90CHF
11:31am EDT
Price Change (% chg)

CHF-1.40 (-0.78%)
Prev Close
CHF179.30
Open
CHF179.30
Day's High
CHF179.40
Day's Low
CHF176.00
Volume
5,620
Avg. Vol
30,131
52-wk High
CHF193.70
52-wk Low
CHF59.00

COPN.S

Chart for COPN.S

About

Cosmo Pharmaceuticals SpA is an Italy-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin disorders.... (more)
No analyst recommendations are available for COPN.S.

Overall

Beta: --
Market Cap (Mil.): €2,221.01
Shares Outstanding (Mil.): 15.00
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): 59.34 33.74 34.44
EPS (TTM): 0.24 -- --
ROI: 5.61 18.86 18.11
ROE: 6.12 19.48 18.84
Search Stocks

BRIEF-Cosmo Pharmaceuticals reports H1 revenue of EUR 41.1 million

July 30 - Cosmo Pharmaceuticals SpA : * Says H1 revenue EUR 41.1 million versus EUR 26.6 million year ago * Says H1 profit after taxes EUR 76.8 million versus EUR 63.3 million year ago * Says H1 operating result EUR 14.6 million versus EUR 6.7 million year ago * Source text for Eikon * Further company coverage

30 Jul 2014

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals , the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

09 Jul 2014

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH, July 9 - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals, the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

09 Jul 2014

BRIEF-Cosmo up 8.3 pct after Salix and subsidiary deal

July 9 - Cosmo Pharmaceuticals SpA : * Opens 8.3 percent higher following deal between subsidiary and Salix

09 Jul 2014

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks